KMA.CAR T

KappaMab (formerly MDX-1097) clinical trials have confirmed that normal leukocytes are not depleted by the antibody with no on-target off-tumour effects1-3, and preclinical KMA.CAR T cell data has confirmed the antibody specificity4. KMA or LMA are expressed on PCs at all stages of MM, and all plasmacytomas and AL patient samples. The increased Ag densities of both KMA and LMA compared to BCMA on RRMM BM PCs indicates antigen persistence on a treatment resistant clone. The combination of increased and persistent antigen density and the specificity of these therapeutic antibodies could provide a significant benefit in the treatment of myeloma and PCDs.1.

Chimeric Antigen Receptor (CAR)-T cell therapy has recently entered the standard of care for relapsed and refractory MM, following the recent FDA-approval of two CAR-T cell products, ide-cel® and cilta-cel®, which target the B cell maturation antigen (BCMA)...The monoclonal antibody, KappaMab (MDX-1097), binds to a conformational epitope on KMA, and has been assessed in phase I, IIa and IIb clinical trials in relapse refractory myeloma patients... Our data demonstrates that anti-KMA CAR-T cell therapy is a novel and potent treatment ready to enter a phase I clinical trial for patients with multiple myeloma.

Chimeric Antigen Receptor (CAR)-T cell therapy has recently entered the standard of care for relapsed and refractory MM, following the recent FDA-approval of two CAR-T cell products, ide-cel® and cilta-cel®, which target the B cell maturation antigen (BCMA)...The monoclonal antibody, KappaMab (MDX-1097), binds to a conformational epitope on KMA, and has been assessed in phase I, IIa and IIb clinical trials in relapse refractory myeloma patients (1)...We successfully generated human anti-KMA CAR-T cells with high and stable CAR expression and a predominately memory T cell phenotype...(1) Spencer et al. Blood Cancer Journal (2019) 9:58